Metastatic breast cancer that is measurable (Stage ) or early breast cancer with a primary tumor size greater than (>)  centimeter (cm) (Stage )
Clinical stage I or II breast cancer for which there will be at least a  week period of time between diagnosis and definitive surgery
Early stage (curable) breast cancer
Patients must have a histologically confirmed HER positive breast cancer (by immunohistochemistry [IHC] + or fluorescence in situ hybridization [FISH] ratio >= .)\r\n* Phase I: unresectable locally advanced or metastatic breast cancer\r\n* Phase II: clinical stage - early stage breast cancer
Clinical evidence for a stage T or T breast cancer
Pathologic or clinical evidence for a stage T breast cancer
The patient must have clinical node negative, stage I breast cancer
COHORT II: The patient must have clinical node negative, stage I breast cancer
Subjects must be females with a histological diagnosis of ductal carcinoma in situ (DCIS) or invasive breast cancer clinical stage T-, N and be candidates for primary resection of this cancer; NOTE: subjects with bilateral cancer are eligible\r\n* Primary tumor stage T- at the time of initial diagnosis and ipsilateral nodes must be N- by clinical evaluation; staging is routinely based on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines and TNM Nomenclature for Breast Cancer from American Joint Committee on Cancer (AJCC) Cancer Staging Manual; all breast cancer patients routinely undergo axillary ultrasound to evaluate nodal involvement
The patient must have stage , I, or II breast cancer; if stage II, the tumor size must be  cm or less
New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.
Subjects with advanced stage breast cancer
Stage II through IIIC HER-/erbB- positive breast cancer with node positive disease.
Locally advanced or inflammatory breast cancer (stage IIIA to IIIC)
Early stage breast cancer (stage I [tumor size >=  cm], II and IIIA)
Early stage breast cancer (Tc-, cN-, cM)
Histologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)
Experiencing their first, stage   IIIA breast cancer diagnosis (either clinical or definitive early stage at enrollment)
Histologically confirmed diagnosis of early stage breast cancer (stage I-III)
PATIENT: Confirmed medical diagnosis of breast or thoracic cancer regardless of stage and followed at DCC for management
Diagnosed with any stage breast, GI, or lung cancer
Diagnosed with stage , I, II, or IIIa breast cancer, confirmed by medical record
Women who have been diagnosed with stage I-IIIA breast cancer will be recruited - years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors); recruit women who have received one of the two most common stage I-IIIA chemotherapy regimens, either docetaxel/cyclophosphamide or doxorubicin/cyclophosphamide followed by paclitaxel to provide uniformity of prior treatment
Have breast cancer stage -IIIA
A diagnosis of local regional breast cancer (stage -IIIa)
Had a previous diagnosis of breast cancer (any type or stage) as confirmed by official medical records
Has been diagnosed with early-stage breast cancer
Women previously diagnosed with stage -IIIA breast cancer
Histologically confirmed stage I, II or III breast cancer (if the patient has had more than one breast cancer, then the most recent diagnosis)
New diagnosis of breast cancer stage -
Stage  or  breast cancer or any other concurrent malignancy including hematological malignancies (i.e. leukemia or lymphoma)
In early survivorship phase, defined as being - months post completion of treatment for stage - breast cancer
PHASE I: Has a first, primary diagnosis of unilateral stage , , , or a breast cancer (patients with bilateral breast cancer will be excluded from participation)
PHASE II: Has a first, primary diagnosis of unilateral stage , , , or a breast cancer
Completed treatment for stage - breast cancer at least two months but not more than  months prior to enrollment.
Women with stage - breast cancer who are within first two rounds of chemotherapy OR women who have stage  breast cancer at initial diagnosis and are initiating first line chemotherapy; note: women with stage  breast cancer must have an Eastern Cooperative Oncology Group (ECOG) performance status of  or 
Women with a history of cancer, any stage, with breast or gynecologic cancer
Stage -IIIA breast cancer survivors and their partner
Stage A  B breast cancer diagnosis
Stage I and II breast cancer patients undergoing active radiation therapy
Have a diagnosis of breast cancer, any stage.
Previous diagnosis of stage  cancer
BREAST CANCER SURVIVORS: Has histologically-confirmed, first-time breast cancer (stage I-IIIB);
Diagnosis of stage I-IIIA breast cancer within past  years (confirmed by medical record review)
Pathologically confirmed diagnosis of breast cancer, clinical stage I-II (T- N M, T- N M); diagnosis must be by needle biopsy; patients diagnosed by surgical excision are excluded; for patients enrolled after receipt and completion of neoadjuvant chemotherapy, the clinical stage must be determined based on pre-chemotherapy assessment
Breast cancer (any stage)
The patient must have a histologically proven diagnosis of stage I through IIIC breast cancer
Participants who are breast cancer free (mammogram negative within  month of testing) with the absence of clinical suspicion of breast cancer on physical exam or with stage II or stage III breast cancer will be invited to participate in the study
Patients without known bone metastases who are newly diagnosed with ? stage  breast cancer, ? stage  lung cancer, or ? stage  prostate cancer (and/or PSA > micrograms/L), including patient with recurrent breast, lung or prostate cancer
Stage  breast cancer
First diagnosis with stage - breast or stage - lung cancer; and voluntary participation